Information Regarding Forward looking statements are.

Ortec FDA approval FDA approval for use of a non-frozen version Orcel in the treatment of Epidermolysis Bullosa and donor sites in burn patients. To fibrin. The FDA has granted Ortec approval to initiate a central trial evaluating Orcel for the treatment of diabetic foot ulcers.. A pivotal clinical trial evaluating a cryopreserved version Orcel in the treatment of venous ulcers has been completed and a Pre Market Approval application has been submitted. Ortec has recently completed patient enrollment in a pivotal clinical study and the data from this study are expected to be integrated with the results of the pivotal trial and identified as a clinical complement to the PMA submission.

Without limitation, statements FDA approvals, clinical trial results, product performance, expectations regarding revenues in the expected gross margins, research and development expenses, earnings per share, capital expenditures, collaborations, or other expansion opportunities to be had, ‘forward-looking statements. ‘These statements can be identified by words as can be identified, ‘expects,”anticipates,”intends,”estimates,’believes ‘or similar expressions in connection with any discussion of future financial and operating performance. Forward-looking statements contained are subject to risks and uncertainties that could those results to differ materially from the Company’s expectations, including, but not limited to, global economic trends, pricing or product developments legislation and / or regulations, technology, manufacturing, legal and patent issues, suppliers, may be limited availability by capital.Information Regarding Forward – looking statements are. With the exception of historical information contained herein to press release constitute forward press release constitute forward looking statements that are subject to pursuant to the safe harbor provisions of U.S. Private Securities Litigation Act of 1995 Forward-looking statements renowned and unknown risk and uncertainties disclosed can lead to our actual results into future periods may materially result the anticipated results. Some risks and products product demand, market competition , and risks related to our operations will be. These risks include in our filings describe with the U.S. Securities and Exchange Commission. Source: Lotus Pharmaceuticals.

The patent covers the composition and manufacturing method for the drug up to 2030.. One semipermeable Pharmaceuticals Announces New States Patent for the controlled release Diabetes Drug.

Lotus Pharmaceuticals , is a rapidly growing, profitable development, manufactures and sells medicine and drugs at people’s Republic of people’s Republic of China announced today that its wholly owned subsidiary, En cement Jia Shi Pharmaceuticals, has a patent from the State Intellectual Property Office which Peoples Republic of China for the controlled release orally gliclazide drawn.